ADHD Medication Update

Useful new research findings released for several different ADHD medications.

Friday May 9th - 11:29am

After announcing the FDA approval of their drug Vyvanse for adult use, the pharmaceutical company Shire shared research data on two of their other Attention Deficit Hyperactivity Disorder (ADHD) drugs, Daytrana and Intuniv, at the American Psychological Association (APA) conference in Washington D.C.

Researchers found Daytrana, an ADHD medication delivered through a patch applied to the skin, was safe and effective for both boys and girls between the ages of six and 12. Clinicians rated 83% of the children "improved" or "very much improved" across gender. In a trial of their new, investigational, nonstimulant drug Intuniv, Shire researchers found a significant improvement in functioning, as measured by symptom reduction, up to 24 hours after the dose was taken by study participants.

For more information, read the full press release from Shire.

Finally, pharmaceutical company Eli Lilly announced yesterday that their nonstimulant drug Strattera has been the first medication approved by the FDA for maintenance of ADHD symptoms. Their research showed that Strattera was significantly more effective than a placebo in preventing symptom relapse over time. This research, and the FDA approval, means that Strattera can be used to effectively treat symptoms over one's lifetime.

Read Eli Lilly's press release for more information.

Copyright © 1998 - 2013 New Hope Media LLC. All rights reserved. Your use of this site is governed by our Terms of Service and Privacy Policy.
ADDitude does not provide medical advice, diagnosis, or treatment. The material on this web site is provided for educational purposes only. See additional information.
New Hope Media, 39 W. 37th Street, 15th Floor, New York, NY 10018